Analyst Expectations for ARS Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
ARS Pharmaceuticals (NASDAQ:SPRY) received four somewhat bullish ratings from analysts in the last quarter, with an average 12-month price target of $16.5, a 2.94% decrease from the previous average price target of $17.00.
June 21, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ARS Pharmaceuticals received four somewhat bullish analyst ratings in the last quarter, with an average 12-month price target of $16.5, down 2.94% from the previous target.
The four somewhat bullish ratings from analysts in the last quarter indicate a positive outlook for ARS Pharmaceuticals. The average 12-month price target of $16.5, although lower than the previous target, still suggests potential upside for the stock. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100